Mycobacteria-based vaccines as immunotherapy for non-urological cancers

Estela Noguera-Ortega*, Sandra Guallar-Garrido, Esther Julián

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

1 Citation (Scopus)


The arsenal against different types of cancers has increased impressively in the last decade. The detailed knowledge of the tumor microenvironment enables it to be manipulated in order to help the immune system fight against tumor cells by using specific checkpoint inhibitors, cell-based treatments, targeted antibodies, and immune stimulants. In fact, it is widely known that the first immunotherapeutic tools as immune stimulants for cancer treatment were bacteria and still are; specifically, the use ofMycobacterium bovisbacillus Calmette-Guerin (BCG) continues to be the treatment of choice for preventing cancer recurrence and progression in non-invasive bladder cancer. BCG and also other mycobacteria or their components are currently under study for the immunotherapeutic treatment of different malignancies. This review focuses on the preclinical and clinical assays using mycobacteria to treat non-urological cancers, providing a wide knowledge of the beneficial applications of these microorganisms to manipulate the tumor microenvironment aiming at tumor clearance.

Original languageAmerican English
Article number1802
Pages (from-to)1-25
Number of pages25
Issue number7
Publication statusPublished - 5 Jul 2020


  • Adjuvant
  • BCG
  • Immunotherapy
  • Mycobacteria antigens
  • Non-tuberculous mycobacteria


Dive into the research topics of 'Mycobacteria-based vaccines as immunotherapy for non-urological cancers'. Together they form a unique fingerprint.

Cite this